CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Core Insights - CRISPR Therapeutics is participating in two upcoming investor conferences in June 2025, showcasing its commitment to engaging with investors and stakeholders [1][2] Group 1: Company Overview - CRISPR Therapeutics has transitioned from a research-stage company to a leader in gene-based medicines, having achieved the historic approval of the first CRISPR-based therapy [3] - The company has a diverse portfolio targeting various disease areas, including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases [3] - The first-ever CRISPR/Cas9 gene-edited therapy was advanced into clinical trials in 2018 for treating sickle cell disease and transfusion-dependent beta thalassemia [3] - CASGEVY (exa-cel) received approval in several countries starting in late 2023 for treating eligible patients with sickle cell disease and beta thalassemia [3] - CRISPR Therapeutics has formed strategic partnerships with leading companies, including Vertex Pharmaceuticals, to enhance its research and development efforts [3] Group 2: Upcoming Events - The company will present at William Blair's 45th Annual Growth Stock Conference on June 3, 2025, at 11:20 a.m. CT [2] - CRISPR Therapeutics will also participate in Goldman Sachs' 46th Annual Global Healthcare Conference on June 9, 2025, at 3:20 p.m. ET [2] - Live webcasts of these presentations will be available on the company's website, with replays archived for 14 days post-presentation [2]